Mechanisms of resistance imatinib (ST1571) in preclinical models and in leukemia patients

被引：44

作者：

Weisberg, E

Griffin, JD

机构：

[1] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA

[2] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Dept Med, Boston, MA USA

来源：

DRUG RESISTANCE UPDATES | 2001年 / 4卷 / 01期

关键词：

D O I：

10.1054/drup.2001.0180

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The tyrosine kinase inhibitor imatinib (ST 157I,Glivec) blocks the activity of the BCR/ABL oncogene and induces hematologic remissions in the majority of patients with chronic myeloid leukemia (CML). Glivec is an aminopyrimidine derivative that interacts with the ATP-binding site within the kinase domain of ABL and several other tyrosine kinases, including c-KIT, PDGF beta receptor, and ARG. The compound is currently in phase III clinical trials. Although patients with chronic phase CML have been found to develop drug resistance only rarely so far, patients in more advanced phases of the leukemia develop resistance frequently. The available information on Glivec resistance will be reviewed. (C) 2001 Harcourt Publishers Ltd.

引用

页码：22 / 28

页数：7

共 51 条

[31]

Mohammed M, 2000, BLOOD, V96, p344A

[32] Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis [J].